Docetaxel Followed by Radical Prostatectomy in Patients With High Risk Localized Prostate Cancer
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01250717|
Recruitment Status : Completed
First Posted : December 1, 2010
Results First Posted : February 4, 2014
Last Update Posted : February 4, 2014
|Condition or disease||Intervention/treatment||Phase|
|Prostate Cancer||Drug: Docetaxel Drug: Dexamethasone Drug: Estramustine Drug: Zoladex Drug: Casodex Procedure: Radical Prostatectomy||Phase 2|
- Participants will receive treatment in the outpatient clinic, where the docetaxel chemotherapy will be placed in a bag of fluid and will be given by vein every three weeks. Participants will take Decadron (dexamethasone) by mouth 12 hours and 1 hour before docetaxel and again 12 hours after docetaxel. They will also take estramustine and casodex by mouth at home. Zoladex (or lupron) will be given subcutaneously (under the skin) 4 times every three months. They will also be started on coumadin beginning at the time of the first docetaxel infusion and continuing until 3 weeks after the 4th cycle of chemotherapy.
- After 2 months (or cycles) of therapy, participants will be evaluated in order to assess the response and toxicity of treatment, including a review of medical history, physical examination, blood tests, including PSA. If there is no evidence of progression or excessive toxicity, treatment will continue for 2 more months in the same manner.
- At the end of 4 months of chemotherapy, participants will be reassessed by the medical oncologist and urologist regarding surgery to remove the prostate.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||28 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Docetaxel Followed by Radical Prostatectomy in Patients With High Risk Localized Prostate Cancer|
|Study Start Date :||January 2001|
|Actual Primary Completion Date :||May 2011|
|Actual Study Completion Date :||May 2011|
Experimental: Docetaxel Followed by Radical Prostatectomy
Given by an IV infusion over 1 hour on day 2 of a three-week cycle
Other Name: TaxotereDrug: Dexamethasone
Orally 12 hours and 1 hour before docetaxel and again 12 hours after docetaxel
Other Name: DecadronDrug: Estramustine
Taken orally three times a day for 5 days for the first part of every three week cycleDrug: Zoladex
Given subcutaneously for 4 doses every three months
Other Name: goserelin acetateDrug: Casodex
Taken orally once a day for 6 months
Other Name: BicalutamideProcedure: Radical Prostatectomy
after the chemo and hormonal therapy all patients have a radiacal prostatectomy
- Pathologic Complete Response Was Assessed by Rigorous Pathological Examination by One of Two Pathologists [ Time Frame: status post prostectomy ]One of two pathologists (SR, EG), assigned the Gleason scores for each patient from pre-treatment prostate biopsies and assessed pathological staging on post- prostatectomy specimens. Staging including a description of all tumor foci within the gland, presence or absence of perineural invasion and/or lymphovascular invasion, presence of extraprostatic extension of tumor (including seminal vesicle invasion), and margin status. The pathologists reviewed the presence or absence of cancer in each prostate gland removed on the study patients. RECIST has to my knowledge not been used for pathological examination in neoadjuvant studies. 0 out of 28 participants acheived complete response. RECIST is not appropriate as cancer within the gland at the time of treatment is not measurable by RECIST. The primary outcome is a pathological complete response.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01250717
|United States, Massachusetts|
|Beth Israel Deaconess Medical Center|
|Boston, Massachusetts, United States, 02115|
|Principal Investigator:||Glenn J. Bubley, MD||Beth Israel Deaconess Medical Center|